BELLUS Health’s portfolio focuses on novel therapeutics for conditions with high unmet medical need.

Its pipeline of projects includes the Company’s lead drug candidate BLU-5937 for chronic cough and several other partnered clinical-stage drug development programs.

BLU-5937 is a selective P2X3 antagonist that has the potential to be a best-in-class therapeutic for chronic cough patients who do not respond to current therapies. BLU-5937 has shown a significant reduction in cough and no effect on taste perception in two separate preclinical models. The Company has completed all preclinical studies on BLU-5937 needed to submit a Clinical Trial Application (“CTA”), including 28-day toxicology animal studies, which demonstrated an excellent safety profile. The Company expects to submit the CTA to Health Canada in the second quarter of 2018 to initiate a Phase 1 clinical study on humans in the third quarter of 2018. Chronic cough is a cough that lasts more than eight weeks and is associated with significant adverse social, psychosocial and physical effects on quality of life. A recent commercial assessment performed by Torreya Insights on behalf of the Company concluded that, in the United States alone, more than 26 million adults have chronic cough and more than 2.6 million of these patients suffer from refractory chronic cough lasting for more than a year.

BELLUS Health also has economic interests in other partnered clinical-stage drug development programs, including KIACTA™ for sarcoidosis, AMO-01 for intellectual disabilities and ALZ-801 for APOE4 homozygous Alzheimer’s disease.


Share this

Sign up for email alerts

Email Address *
Enter the code shown above.